 Equillium Inc. EQ, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd BSE code: 532523, NSE: BIOCON, an innovation-led global biopharmaceuticals company, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand. Equillium had originally secured exclusive rights to develop and commercialize Biocons novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017. 